LUCAR-G79 T cells not checked
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Prior to infusion of the LUCAR-G79 T cells, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.”In the company’s words, NCT07049081 on ClinicalTrials.gov
- Tested for
- Relapsed/Refractory Autoimmune Diseases
- Main trialPhase 1
- “This is a prospective, single-arm, open-label and dose-escalation Investigator Initialed study to evaluate LUCAR-G79 in adult subjects with relapsed/refractory autoimmune diseases.”In the company’s words, NCT07049081 on ClinicalTrials.gov
Other drugs for Relapsed/Refractory Autoimmune Diseases
- RilzabrutinibSanofi · Phase 3
- IMU-838Immunic AG · Phase 3
- TirzepatideEli Lilly · Phase 3
- Descartes-08Cartesian Therapeutics · Phase 3
- HSK39297Haisco Pharmaceutical Group Co., Ltd. · Phase 3
- GefurulimabAlexion Pharmaceuticals, Inc. · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Terminated | 20 Mar 2026 | A Study of LUCAR-G79 in Subjects With Relapsed/Refractory Autoimmune Diseases |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026